Literature DB >> 12764132

The reverse activity of human acid ceramidase.

Nozomu Okino1, Xingxuan He, Shimon Gatt, Konrad Sandhoff, Makoto Ito, Edward H Schuchman.   

Abstract

An overexpression system was recently developed to produce and purify recombinant, human acid ceramidase. In addition to ceramide hydrolysis, the purified enzyme was able to catalyze ceramide synthesis using [14C]lauric acid and sphingosine as substrates. Herein we report detailed characterization of this acid ceramidase-associated "reverse activity" and provide evidence that this reaction occurs in situ as well as in vitro. The pH optimum of the reverse reaction was approximately 5.5, as compared with approximately 4.5 for the hydrolysis reaction. Non-ionic detergents and zinc cations inhibited the activity, whereas most other cations were stimulatory. Of note, sphingomyelin also was very inhibitory toward this reaction, whereas the anionic lipids, phosphatidic acid and phosphatidylserine, were stimulatory. Of various sphingosine stereoisomers tested in the reverse reaction, only the natural, D-erythro form could efficiently serve as a substrate. Using D-erythro-sphingosine and lauric acid as substrates, the reaction followed normal Michaelis-Menten kinetics. The Km and Vmax values toward sphingosine were 23.75 microM and 208.3 pmol/microg/h, respectively, whereas for lauric acid they were 73.76 microM and 232.5 pmol/microg/h, respectively. Importantly, the reverse activity was reduced in cell lysates from a Farber disease patient to the same extent as the acid ceramidase activity. Furthermore, when 12-(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)) (NBD)-conjugated lauric acid and sphingosine were added to cultured lymphoblasts from a Farber disease patient in the presence of fumonisin B (1), the conversion to NBD-ceramide was reduced approximately 30% when compared with normal cells. These data provide important new information on human acid ceramidase and further document its central role in sphingolipid metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12764132     DOI: 10.1074/jbc.M303310200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  The identification of the endogenous ligands of natural killer T cells reveals the presence of mammalian α-linked glycosylceramides.

Authors:  Lisa Kain; Bill Webb; Brian L Anderson; Shenglou Deng; Marie Holt; Anne Costanzo; Anne Constanzo; Meng Zhao; Kevin Self; Anais Teyton; Chris Everett; Mitchell Kronenberg; Dirk M Zajonc; Albert Bendelac; Paul B Savage; Luc Teyton
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

Review 2.  Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.

Authors:  Alfred H Merrill
Journal:  Chem Rev       Date:  2011-09-26       Impact factor: 60.622

3.  In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease.

Authors:  Shobha Ramsubir; Takahiro Nonaka; Carmen Bedia Girbés; Stéphane Carpentier; Thierry Levade; Jeffrey A Medin
Journal:  Mol Genet Metab       Date:  2008-09-20       Impact factor: 4.797

4.  Regulation of the sphingosine-recycling pathway for ceramide generation by oxidative stress, and its role in controlling c-Myc/Max function.

Authors:  Iyad Sultan; Can E Senkal; Suriyan Ponnusamy; Jacek Bielawski; Zdzislaw Szulc; Alicja Bielawska; Yusuf A Hannun; Besim Ogretmen
Journal:  Biochem J       Date:  2006-01-15       Impact factor: 3.857

Review 5.  Ceramidases, roles in sphingolipid metabolism and in health and disease.

Authors:  Nicolas Coant; Wataru Sakamoto; Cungui Mao; Yusuf A Hannun
Journal:  Adv Biol Regul       Date:  2016-10-11

6.  Novel pathway of ceramide production in mitochondria: thioesterase and neutral ceramidase produce ceramide from sphingosine and acyl-CoA.

Authors:  Sergei A Novgorodov; Bill X Wu; Tatyana I Gudz; Jacek Bielawski; Tatiana V Ovchinnikova; Yusuf A Hannun; Lina M Obeid
Journal:  J Biol Chem       Date:  2011-05-25       Impact factor: 5.157

Review 7.  Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.

Authors:  Daniel Canals; David M Perry; Russell W Jenkins; Yusuf A Hannun
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

Review 8.  The role of ceramides in metabolic disorders: when size and localization matters.

Authors:  Sarah M Turpin-Nolan; Jens C Brüning
Journal:  Nat Rev Endocrinol       Date:  2020-02-14       Impact factor: 43.330

9.  The role of sphingolipids and ceramide in pulmonary inflammation in cystic fibrosis.

Authors:  Katrin Anne Becker; Joachim Riethmüller; Yang Zhang; Erich Gulbins
Journal:  Open Respir Med J       Date:  2010-03-30

Review 10.  Molecular targeting of acid ceramidase: implications to cancer therapy.

Authors:  Youssef H Zeidan; Russell W Jenkins; John B Korman; Xiang Liu; Lina M Obeid; James S Norris; Yusuf A Hannun
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.